Merck & Company Inc (MRK)vsVyne Therapeutics Inc (VYNE)
MRK
Merck & Company Inc
$113.56
+0.36%
HEALTHCARE · Cap: $277.02B
VYNE
Vyne Therapeutics Inc
$0.67
+0.53%
HEALTHCARE · Cap: $21.39M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 11538146% more annual revenue ($65.77B vs $570,000). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 53/100 (C-).
MRK
Buy53
out of 100
Grade: C-
VYNE
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-15.7%
Fair Value
$97.76
Current Price
$113.56
$15.80 premium
Margin of Safety
+36.0%
Fair Value
$0.87
Current Price
$0.67
$0.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 38.1%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 54.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -67.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.
Bull Case : VYNE
The strongest argument for VYNE centers on Price/Book, Revenue Growth. Revenue growth of 54.8% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : VYNE
The primary concerns for VYNE are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while VYNE is a hypergrowth play — different risk/reward profiles.
VYNE carries more volatility with a beta of 1.95 — expect wider price swings.
VYNE is growing revenue faster at 54.8% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (53/100 vs 34/100). VYNE offers better value entry with a 36.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Vyne Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?